Raynaud's Phenomenon Secondary to Systemic Sclerosis
Immunology·MeSH: Scleroderma, Systemic
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| iloprost | GT Biopharma, Inc. (GTBP) |
Frequently asked questions
How many drugs are in development for Raynaud's Phenomenon Secondary to Systemic Sclerosis?
BioSniper tracks 1 drug in development for Raynaud's Phenomenon Secondary to Systemic Sclerosis across 1 company.
How many clinical trials target Raynaud's Phenomenon Secondary to Systemic Sclerosis?
There are 1 clinical trial targeting Raynaud's Phenomenon Secondary to Systemic Sclerosis tracked by BioSniper.
Deep-dive into Raynaud's Phenomenon Secondary to Systemic Sclerosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis